Literature DB >> 31472119

Spinal TASK-1 and TASK-3 modulate inflammatory and neuropathic pain.

Guadalupe García1, Roxana Noriega-Navarro1, Vladimir A Martínez-Rojas1, Erika J Gutiérrez-Lara1, Norma Oviedo2, Janet Murbartián3.   

Abstract

This study assessed the participation of spinal TWIK-related acid-sensitive K+ channels 1 and 3 (TASK-1 and TASK-3) in inflammatory (formalin test) and neuropathic (spinal nerve ligation, SNL) pain in rats. Intrathecal pre-treatment (-10 min) with the TASK-1 blocker ML365 or TASK-3 blocker PK-THPP, but not vehicle, enhanced in a dose-dependent manner 1% formalin-induced acute and long-lasting secondary mechanical allodynia and mechanical hyperalgesia in rats. In contrast, intrathecal pre-treatment with terbinafine, an activator of TASK-3, reduced formalin-induced flinching and allodynia/hyperalgesia. Both blockers and terbinafine had similar effects on female and male rats. In addition, intrathecal injection of ML365 or PK-THPP blocked the terbinafine-induced antiallodynic effect in neuropathic rats, but they did not modify baseline withdrawal threshold in naïve or sham-operated rats. TASK-1 and TASK-3 mRNA and protein were expressed in L4 and L5 dorsal root ganglia (DRG) and dorsal and ventral spinal cord of naïve animals. Interestingly, formalin injection increased TASK-1 expression in ipsilateral L5 DRG, but not in the spinal cord. Moreover, formalin injection transiently enhanced TASK-3 expression in ipsilateral L5 DRG and dorsal spinal cord. In contrast, SNL down-regulated TASK-3 expression in the ipsilateral L4 and L5 DRG but not in dorsal or ventral spinal cord, while SNL did not modify TASK-1 expression at any tissue. The pharmacological and molecular results suggest that TASK-1 and TASK-3 have a relevant antinociceptive role in inflammatory and neuropathic pain.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allodynia; Hyperalgesia; Inflammatory pain; Neuropathic pain; TASK-1; TASK-3

Mesh:

Substances:

Year:  2019        PMID: 31472119     DOI: 10.1016/j.ejphar.2019.172631

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Alkalinization of the Synaptic Cleft during Excitatory Neurotransmission.

Authors:  Peter J Niesman; Valeria Silva
Journal:  J Neurosci       Date:  2020-08-12       Impact factor: 6.167

2.  TASK-3: New Target for Pain-Relief.

Authors:  Wen-Jing Ren; Henning Ulrich; Alexey Semyanov; Peter Illes; Yong Tang
Journal:  Neurosci Bull       Date:  2020-05-26       Impact factor: 5.203

3.  Genomic Action of Sigma-1 Receptor Chaperone Relates to Neuropathic Pain.

Authors:  Shao-Ming Wang; Nino Goguadze; Yuriko Kimura; Yuko Yasui; Bin Pan; Tzu-Yun Wang; Yoki Nakamura; Yu-Ting Lin; Quinn H Hogan; Katherine L Wilson; Tsung-Ping Su; Hsiang-En Wu
Journal:  Mol Neurobiol       Date:  2021-01-18       Impact factor: 5.590

4.  A "Target Class" Screen to Identify Activators of Two-Pore Domain Potassium (K2P) Channels.

Authors:  David McCoull; Emma Ococks; Jonathan M Large; David C Tickle; Alistair Mathie; Jeffrey Jerman; Paul D Wright
Journal:  SLAS Discov       Date:  2020-12-29       Impact factor: 3.341

Review 5.  Contribution of Neuronal and Glial Two-Pore-Domain Potassium Channels in Health and Neurological Disorders.

Authors:  Yuncheng Luo; Lu Huang; Ping Liao; Ruotian Jiang
Journal:  Neural Plast       Date:  2021-08-12       Impact factor: 3.599

Review 6.  Development of Non-opioid Analgesics Targeting Two-pore Domain Potassium Channels.

Authors:  Lu Huang; Guangyin Xu; Ruotian Jiang; Yuncheng Luo; Yunxia Zuo; Jin Liu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.